

DAFTAR PUSTAKA

- Abdel Wahab, M. M., et al. (2023). Molecular detection of *Mycobacterium leprae* in household contacts after chemoprophylaxis: Implications for transmission dynamics. *PLOS Neglected Tropical Diseases*, 17(6), e0011492. <https://doi.org/10.1371/journal.pntd.0011492>
- Alinda, M. D., Geani, S., Agusni, R. I., Kusumaputra, B. H., Reza, N. R., Prakoeswa, C. R. S., & Listiawan, M. Y. (2020). Diagnosis and Management of Leprosy. *Berkala Ilmu Kesehatan Kulit Dan Kelamin*, 32(2), 149–157. <https://doi.org/10.20473/BIKK.V32.2.2020.149-157>
- Badan Pusat Statistik. (2023). *Statistik Penduduk Usia Kerja 2023*. Badan Pusat Statistik Republik Indonesia.
- Banerjee, S., Sarkar, K., Gupta, S., & Mahapatra, P. S. (2020). PCR-based detection of *Mycobacterium leprae* in nasal swabs of leprosy contacts: Implications for transmission. *Journal of Medical Microbiology*, 69(9), 1211–1218. <https://doi.org/10.1099/jmm.0.001247>
- Barbosa, D. R., et al. (2021). Duration and intensity of exposure as key determinants of leprosy transmission in endemic settings. *Infectious Disease Reports*, 13(4), 957–965.
- B. Sekar. (2016). Bacteriology of Leprosy. In Kumar Bhushan & Kumar Kar Hemanta (Eds.), *IAL Textbook of Leprosy* (Secon Edition, pp. 90–99). Jaypee Brothers Medical Publishers.
- Brito Gonçalves, M. J., Lima, L. A., Rodrigues, T. S., & Leite, T. B. (2024). *Prevalence of paucibacillary cases of leprosy in Brazil: a 20-Year Systematic Review and Meta-Analysis*. *Frontiers in Medicine*, 11, 1401685. <https://doi.org/10.3389/fmed.2024.1401685>
- Bryceson Anthony, & Pfaltzgraff Roy E. (1990). *Leprosy Third Edition*. Edinburgh: Churchill Livingstone.
- Cabral, P. B., et al. (2020). Long-term exposure and household dynamics associated with leprosy in endemic communities. *PLoS Neglected Tropical Diseases*, 14(11), e0008827.
- Campbell, P. O., Bauro, T., Rimon, E., Timeon, E., Bland, C., Ioteba, N., Douglas, N. M., Cunanan, A., & Chambers, S. T. (2024). *Single-Dose Rifampicin Leprosy Chemoprophylaxis for Household Contacts in Kiribati: An Audit of a Combined Retrospective and Prospective Approach*. *Tropical Medicine and Infectious Disease*, 9(3), 58. <https://doi.org/10.3390/tropicalmed9030058>
- Chen, K. H., Lin, C. Y., Su, S. B., and Chen, K. T. (2022). Leprosy: A Review of Epidemiology, Clinical Diagnosis, and Management. *Journal of Tropical Medicine*. Doi. [10.1155/2022/8652062](https://doi.org/10.1155/2022/8652062)

- Costa, R. D., et al. (2022). Environmental and spatial determinants associated with leprosy in endemic regions. *PLoS Neglected Tropical Diseases*, 16(3), e0010217.
- de Macedo, A. C., Guimarães, J. A., Rodrigues, R. O., Araújo, T. D. V., Tavares, C. M., Cabral, P. B., de Moraes-Pinto, M. I., & Nagao-Dias, A. T. (2018). Serum anti-phenolic glycolipid-1 IgA correlates to IgM isotype in leprosy patients: a possible candidate for seroepidemiological surveys? *Journal of Clinical Laboratory Analysis*, 32(3). <https://doi.org/10.1002/JCLA.22276>
- de Souza Dias, R. F., et al. (2016). Spatial analysis of anti-PGL-1 seropositivity to identify leprosy transmission hotspots. *PLoS Neglected Tropical Diseases*, 10(5), e0004710.
- Dianita, R. D. (2020). Perbandingan determinan kejafdlan kusta pada masyarakat daerah perkotaan dan pedesaan. *HIGEIA: Journal of Public Health Research and Development*, 4(4), 678–688.
- Douglas, J. T., et al. (2004). Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Vol. 11(5): 897-900. **DOI:** 10.1128/CDLI.11.5.897-900.2004.
- Duthie, M. S., & Balagon, M. F. (2016a). Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. *Risk Management and Healthcare Policy*, 9, 43–53. <https://doi.org/10.2147/RMHP.S76058>
- Espinosa, O. A., Benevides Ferreira, S. M., Longhi Palacio, F. G., Cortela, D. D. C. B., & Ignotti, E. (2018). Accuracy of Enzyme-Linked Immunosorbent Assays (ELISAs) in Detecting Antibodies against *Mycobacterium leprae* in Leprosy Patients: A Systematic Review and Meta-Analysis. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2018. <https://doi.org/10.1155/2018/9828023>
- Fantoni, O. J. J., et al. (2023). Comparison of antiphenolic glycolipid-1 antibody levels in seropositive contacts of leprosy after 2 years of single-dose rifampicin as postexposure prophylaxis. *International Journal of Mycobacteriology*. Vol. 12(4): 399-406. **DOI:** 10.4103/ijmy.ijmy_118_23
- Fürst, T., Héritier, S., Schindler, C., Lergier, N., Choun, N., & Kasang, C. (2018). Retrospective active case finding in Cambodia: Experience of small mobile teams and contact tracing. *Acta Tropica*, Vol.180: 10-18. <https://doi.org/10.1016/j.actatropica.2017.12.025>
- Fontes, A. N. B., et al. (2017). Genotyping of *Mycobacterium leprae* for better understanding of leprosy transmission in Fortaleza, northeastern Brazil. *PLoS Neglected Tropical Diseases*. Vol. 11(12):1-20. <https://doi.org/10.1371/journal.pntd.0006117>.
- Gibson, R. S. (2005). *Principles of Nutritional Assessment* (2nd ed.). Oxford University Press.
- Hungria, E. M., et al. (2021). Subclinical infection in household contacts of leprosy patients: Molecular and serological approaches. *PLoS Neglected Tropical Diseases*. Vol. 15(2). <https://doi.org/10.1371/journal.pntd.0009136>.

- Izumi, S., et al. (1999). Serological survey of leprosy in Indonesia using PGL-1 ELISA. *International Journal of Leprosy and Other Mycobacterial Diseases*, 67(4), 389–395.
- Jafar, N., Edriss, H., & Nugent, K. (2016). The Effect of Short-Term Hyperglycemia on the Innate Immune System. *The American Journal of the Medical Sciences*, 351(2), 201–211. <https://doi.org/10.1016/J.AMJMS.2015.11.011>
- Kementerian Kesehatan Republik Indonesia. (2022). *Laporan Validasi Data Kusta Nasional*. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit.
- Krismawati, H., Oktavian, A., Maladan, Y., & Wahyuni, T. (2020). Risk factor for Mycobacterium leprae detection in household contacts with leprosy patients: a study in Papua, East Indonesia. *Medical Journal of Indonesia*, 29(1), 64–70. <https://doi.org/10.13181/mji.oa.192962>
- Kumar, A., Parkash, O., & Girdhar, B. K. (2014a). Analysis of Antigens of Mycobacterium leprae by Interaction to Sera IgG, IgM, and IgA Response to Improve Diagnosis of Leprosy . *BioMed Research International*. <https://doi.org/10.1155/2014/283278>
- Lima, L. N., Illarramendi, X., Sales, A. M., Nery, J. A. C., Duthie, M. S., & Sarno, E. N. (2021). Anti-PGL-1 serology and surveillance of leprosy contacts in Brazil: A population-based study. *PLoS Neglected Tropical Diseases*, 15(3), e0009208. <https://doi.org/10.1371/journal.pntd.0009208>
- Lourenço, D. S. D., & collaborators. (2024). Detection of subclinical Mycobacterium leprae infection in children, contacts of leprosy cases, Fortaleza – Ceará, Brazil. *PLOS Neglected Tropical Diseases*, 18(7), e0012345. <https://doi.org/10.1371/journal.pntd.0012345>
- Lages, D. d. S., Maciel, I. C. L., Vidal, S. L., & Lana, F. C. F. (2025). Spatial, social and serological factors in the prevalence and risk of leprosy in areas of high endemicity: An integrative review. *Infectious Disease Reports*, 17(3), 57. <https://doi.org/10.3390/idr17030057>
- Maria, I., Goulart, B., Luiz, ., & Goulart, R. (2008). Leprosy: diagnostic and control challenges for a worldwide disease. *Arch Dermatol Res*, 300, 269–290. <https://doi.org/10.1007/s00403-008-0857-y>
- Moet, F. J., et al. (2008). Effectiveness of single-dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: A cluster randomised controlled trial. *The New England Journal of Medicine*, 358(2), 163–172. <https://doi.org/10.1056/NEJMoa072954>.
- Moestopo, O., Gunawan, H., & Dahlan, A. (2016). Comparison of Effectiveness between Rifampicin Ofloxin-Minocycline Regimen and Multidrug Therapy-World Health Organization in Multibacillary Leprosy Patients. *Althea Medical Journal*, 3(4), 661–665. <https://doi.org/10.15850/AMJ.V3N4.955>
- Muhammad Mimbar. (2021). Profilaksis Pada Penyakit Kusta. *Jurnal Sains, Teknologi, Ekonomi, Sosial Dan Budaya*, 5(3), 85–88.

- Novita, B. D. (2020b). Chemoprophylaxis Versus Immunoprophylaxis In Tuberculosis And Leprosy Infection. *JURNAL WIDYA MEDIKA*, 6(1), 65–71. <http://journal.wima.ac.id/index.php/JWM/article/view/2504>
- Nath Indira, & Chanduvula Mehervani. (2016). Immunological Aspects. In Kumar Bhushan & Kumar Kar Hemanta (Eds.), *IAL Textbook of Leprosy* (Second Edition, pp. 105–115).
- Niitsuma, E. N. A., et al. (2025). *Anti-PGL-I seropositivity and development of leprosy among contacts in a hyperendemic region of Brazil. Tropical Medicine and Infectious Disease.*
- Oldenburg, R., & Demangel, C. (2017). Pathogenic and immunosuppressive properties of mycobacterial phenolic glycolipids. *Biochimie*, 141, 3–8. <https://doi.org/10.1016/J.BIOCHI.2017.03.012>
- Palit Aparna, S Ragunatha, & Inamadar arun C. (2016). History Taking and Clinical Examination. In Kumar Bhushan & Kumar Kar Hemanta (Eds.), *IAL Textbook of Leprosy* (Second Edition, pp. 207–211). Jaypee Brothers Medical Publishers.
- Pescarini, J. M., Strina, A., Nery, J. S., Skalinski, L. M., Andrade, K. V. F., Penna, M., Brickley, E. B., Rodrigues, L. C., & Barreto, M. L. (2018). *Socioeconomic risk markers of leprosy in high-burden countries: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases*, 12(7), e0006622. <https://doi.org/10.1371/journal.pntd.0006622>
- Pertiwi, A. N. A., & Syahrul, F. (2024). Risk factors for leprosy: A systematic review. *The Indonesian Journal of Public Health*, 19(3), 575–589. <https://orcid.org/0009-0008-2529-7521>.
- Preston, S., Heuveline, P., & Guillot, M. (2001). *Demography: Measuring and Modeling Population Processes*. Blackwell Publishers.
- Puspitasari, N. W. R., Assa, I., Adimuntja, N. P., Bouway, D. Y., Pariaribo, K., & Asriati, A. (2023). *Faktor risiko kejadian kusta di wilayah kerja Puskesmas Elly Uyo Kota Jayapura. Jurnal Kesehatan Masyarakat*, 11(4), 452–463. <https://doi.org/10.14710/jkm.v11i4.36713>
- Rani Rajni. (2016). Immunogenetics of Leprosy. In Kumar Bhushan & Kumar Kar Hemanta (Eds.), *IAL Textbook of Leprosy* (Second Edition, pp. 74–81). Jaypee Brothers Medical Publishers.
- Richardus, J. H., et al. (2021). Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an international feasibility programme. *The Lancet Global Health*. Vol. 9(1):81–90. [https://doi.org/10.1016/S2214-109X\(20\)30396-X](https://doi.org/10.1016/S2214-109X(20)30396-X).
- Rodrigues, L. C., Smith, W. C. S., & Heukelbach, J. (2023). Biomarkers of exposure and infection in leprosy contacts: Limitations and future perspectives. *The Lancet Infectious Diseases*, 23(4), e109–e118. [https://doi.org/10.1016/S1473-3099\(22\)00563-1](https://doi.org/10.1016/S1473-3099(22)00563-1)

- Saha, U. R., Chowdhury, A. S., Roy, J. C., Alam, K., Nieboer, D., Verbiest-Richardus, R., Geluk, A., & Richardus, J. H. (2025). Risk factors and leprosy incidence among contacts in Bangladesh: A multilevel analysis. *PLOS Neglected Tropical Diseases*, 19(9), e0013465. <https://doi.org/10.1371/journal.pntd.0013465>
- Sales, A. M., Ponce de Leon, A., Düppre, N. C., Hacker, M. A., Nery, J. A. C., Sarno, E. N., & Penna, M. L. F. (2011). *Leprosy among patient contacts: A multilevel study of risk factors*. *PLoS Neglected Tropical Diseases*, 5(3), e1013. <https://doi.org/10.1371/journal.pntd.0001013>
- Schreuder, P. A., et al. (2020). Spatial clustering of leprosy in endemic settings. *Leprosy Review*, 91(2), 155–168.
- Sengupta, U. (2019). Recent laboratory advances in diagnostics and monitoring response to treatment in leprosy. *Indian Dermatology Online Journal*, 10(2), 106–114. https://doi.org/10.4103/IDOJ.IDOJ_260_18
- Taal, A. T., Barreto, J. G., Santos de Sousa, G. D., da Rocha, A. M., Lima Ferreira, N. N., & Menezes da Silva, J. A. (2022). Determining target populations for leprosy prophylactic interventions: a GIS-based cluster analysis in Pasuruan and Pamekasan, Indonesia. *BMC Infectious Diseases*, 22, 1033. <https://doi.org/10.1186/s12879-022-07103-0>
- Tabri, F., Maskur, Z., Amiruddin, M. D., & Makalew, H. L. (2017). Analysis of SGOT, SGPT, and IgM anti PGL-1 in Multibacillary Leprosy Patient after Multi Drug Therapy. *Global Journal of Health Science*, 9(9), p36. <https://doi.org/10.5539/GJHS.V9N9P36>
- Tawfik, G. M., Biala, M., Yousef, Y. M., Tiwari, R., Dobs, M., Lotfy, C. I., Farrag, D. A., Hue, A. T., Yotsu, R. R., & Huy, N. T. (2021). Efficacy of chemoprophylaxis and immunoprophylaxis in leprosy prevention: a systematic review and network meta-analysis of randomized controlled trials. *Clinical Microbiology and Infection*, 27(12), 1754–1761. <https://doi.org/10.1016/J.CMI.2021.07.032>
- Teixeira, C. S., Pescarini, J. M., Alves, F. J. O., Nery, J. S., Sanchez, M. N., Teles, C., et al. (2020). *Incidence of and factors associated with leprosy among household contacts of patients with leprosy in Brazil*. *JAMA Dermatology*, 156(6), 640–648. <https://doi.org/10.1001/jamadermatol.2020.0653>
- Tuturoop, K. L., Adimuntja, N. P., & Borlyin, D. E. (2022). Faktor risiko kejadian penyakit kusta di Puskesmas Kotaraja. *Jambura Journal of Epidemiology*. (1), 1–10. <https://doi.org/10.37905/jje.v1i1.14622>.
- Van Hooij, A., & Geluk, A. (2021). In search of biomarkers for leprosy by unraveling the host immune response to *Mycobacterium leprae*. *Immunological Reviews*. Vol. 301(1): 175-192. <https://doi.org/10.1111/imr.12952>.
- Wang, H., Ma, Y., Li, Y., Wang, Y., He, Y., & Zhang, L. (2013). *Evaluation of anti-MMP-II and anti-PGL-I antibody responses for serological diagnosis of leprosy*. *Clinical and Vaccine Immunology*. Vol. 20(8), 1149–1155. <https://doi.org/10.1128/CVI.00239-13>.

World Health Organization (WHO). (2020). *Body mass index – BMI classification*.

World Health Organization. (2024). Global Leprosy (Hansen's Disease) Update: Progress towards zero leprosy. *Weekly Epidemiological Record*, 99(36), 429–448.

Yan, W., Xing, Y., Yuan, L. C., Yang, R. D., Tan, F. Y., Zhang, Y., & Li, H. Y. (2014). *Application of RLEP real-time PCR for detection of Mycobacterium leprae DNA in paraffin-embedded skin biopsy specimens for diagnosis of paucibacillary leprosy*. *PLoS Neglected Tropical Diseases*, 8(1), e2617. <https://doi.org/10.1371/journal.pntd.000261>

Younoussa, A., et al. (2023). Anti-PGL-I seropositivity and its associated factors in leprosy endemic communities. *BMC Infectious Diseases*, 23(1), 1–12.